For investors
An evidence-led approach to health technology.
CHP is being built as an international, clinically integrated HealthTech investment platform. This page describes the thesis and the disciplines we intend to apply. It is not an offer, a solicitation or an invitation to invest.
The thesis
Four ideas that shape our decisions.
- 01
Evidence-led selection
Clinical review and validation inform whether an opportunity progresses.
- 02
Staged deployment
Capital follows milestones rather than a single upfront commitment.
- 03
Adoption focus
Workflow, procurement and reimbursement examined as part of the thesis.
- 04
Regional relevance
Global sourcing assessed against credible deployment opportunities across international markets.
Risk disciplines
How we intend to approach risk.
- Technology risk
- Independent clinical review, pilots and evidence generation.
- Adoption risk
- Clinician engagement, nursing workflow assessment, usability and operational testing.
- Regulatory risk
- Specialist review of the regulatory, reimbursement and market-access pathway.
- Commercial risk
- Assessment of provider demand, payer engagement, distribution and strategic channels.
These disciplines are intended to improve decision-making. They do not eliminate investment, implementation or clinical risk.
Important context
What this page does not say.
CHP is a company in formation. Nothing on this site confirms incorporation, licensing, regulatory permissions, a launched fund, committed capital or a completed portfolio.
We publish no fund size, target return, investment size or performance information. Any discussion of a potential investment relationship would take place privately and would be subject to the applicable legal and regulatory requirements.
Please read our important disclosures.
Private enquiry
Request a conversation.
Share your details and we will review your enquiry. Please keep your message non-confidential.